Fulcrum Therapeutics (FULC) Enterprise Value (2019 - 2026)

Fulcrum Therapeutics (FULC) has reported Enterprise Value for 9 consecutive years, with -$318.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Enterprise Value fell 648.66% year-over-year to -$318.8 million; the TTM figure through Jun 2026 stood at -$318.8 million (down 648.66% YoY), while the FY2025 annual figure was -$352.3 million, down 46.17% from the prior year.
• Enterprise Value rose to -$318.8 million in Q2 2026 per FULC's latest filing, from -$333.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$30.1 million in Q3 2023 and bottomed at -$352.3 million in Q4 2025.
• Historically, Enterprise Value has averaged -$125.8 million across 5 years, with a median of -$57.6 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 66.93% — and 2026, when it tumbled 690.26%.
• Fulcrum Therapeutics' Enterprise Value stood at -$35.1 million in 2022, then sank by 573.03% to -$236.2 million in 2023, then slipped by 2.03% to -$241.0 million in 2024, then plunged by 46.17% to -$352.3 million in 2025, then climbed by 9.5% to -$318.8 million in 2026.
• Business Quant data shows FULC's Enterprise Value at -$318.8 million in Q2 2026, -$333.3 million in Q1 2026, and -$352.3 million in Q4 2025.